POC Electrical Sensing-Based Blood Testing Technology Unveiled at ADLM 2024
|
By LabMedica International staff writers Posted on 30 Jul 2024 |

Chronus Health (Fremont, CA, USA) is showcasing its innovative platform powered by electrical sensing-based blood testing technology at the ADLM 2024 conference taking place in Chicago from July 28 to August 1.
Chronus has developed the first-of-a-kind electrical sensing-based, real-time blood testing system for use in urgent care centers, skilled nursing facilities, infusion centers, retail clinics, as well as primary care and specialty clinics. This technology will reduce the time to diagnosis and lower overall healthcare costs since blood samples are analyzed on-site rather than sent to central labs for analysis. Chronus’ platform can uniquely support cell counting, chemistry assays (electrolytes, small molecules, and proteins), and immunoassays (proteins). This comprehensive solution, often regarded as the “holy grail” of diagnostics, has remained elusive until now, as past attempts to miniaturize existing technologies have lacked technical feasibility and cost-effectiveness.
The world’s first real-time electrical blood test system offers significant advantages in cost, size, and simplicity through the use of electrical sensors that facilitate miniaturization and reduce complexity. By leveraging a proprietary electrical sensing approach that integrates microfluidic sensors, machine learning, and aptamers, Chronus is poised to be the first to successfully deliver a platform capable of testing multiple blood panels outside the central lab setting. With 60% of all blood tests conducted outside hospitals, the company is at the forefront of providing fast and accurate blood testing at the point of care, at a lower price point.
“No one likes waiting for blood test results – neither doctors nor patients or their families,” said Caesar Djavaherian, MD, Co-Founder and Chief Clinical Innovation Officer of Carbon Health. “Now we have a technology that can cost-effectively provide results at the point of care, leading to better patient outcomes and increased provider satisfaction. We look forward to launching a clinical trial using the Chronus system soon.”
“We are creating a new era for point-of-care testing, with a platform slated to revolutionize the diagnostics industry,” said Anand Parikh, CEO and Co-Founder of Chronus Health. “The foundation of processing lab work has remained the same for decades, and just as other industries have benefited from the innovation in electrical technology, so too will healthcare.”
Related Links:
Chronus Health
Latest ADLM 2024 News
- EKF Diagnostics Showcases Range of Diabetes and Hematology POC Devices
- HemoSonics Demonstrates Breakthrough in Point-Of-Care Viscoelastic Hemostasis Testing
- Cytovale Demonstrates 8-Minute Sepsis Diagnostic Test
- Inpeco Launches Next-Generation Total Lab Automation System
- Messe Düsseldorf Promotes International “MEDICAlliance” Portfolio at ADLM 2024
- Tianlong Showcases Latest Products in Molecular Diagnostics, Biochemistry, Immunology and POC Testing
- QuidelOrtho Demonstrates Advanced Diagnostic Laboratory Solutions across Healthcare Continuum
- HORIBA Unveils New Compact Hematology Analyzers with Combined ESR and CBC/Diff
- Beckman Coulter Introduces Latest Innovations in Clinical Diagnostics
- Abbott Demonstrates End to End Laboratory Solutions
- Werfen Introduces GEM Premier 7000 with iQM3 Blood Gas Testing System
- Thermo Fisher Showcases Diagnostics Innovation Across Therapeutic Areas
- Siemens Demonstrates Human-Centered Engineering and Automation for Laboratory Testing
- Roche Showcases Solutions for Laboratories of the Future
- World's First 5-Minute Real-Time PCR Instrument Debuts at ADLM 2024
- ADLM 2024 Showcases Breakthrough Innovations Shaping Future of Clinical Testing
Channels
Clinical Chemistry
view channel
New PSA-Based Prognostic Model Improves Prostate Cancer Risk Assessment
Prostate cancer is the second-leading cause of cancer death among American men, and about one in eight will be diagnosed in their lifetime. Screening relies on blood levels of prostate-specific antigen... Read more
Extracellular Vesicles Linked to Heart Failure Risk in CKD Patients
Chronic kidney disease (CKD) affects more than 1 in 7 Americans and is strongly associated with cardiovascular complications, which account for more than half of deaths among people with CKD.... Read moreMolecular Diagnostics
view channel
Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test
Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more
Blood Test Detects Early-Stage Cancers by Measuring Epigenetic Instability
Early-stage cancers are notoriously difficult to detect because molecular changes are subtle and often missed by existing screening tools. Many liquid biopsies rely on measuring absolute DNA methylation... Read more
“Lab-On-A-Disc” Device Paves Way for More Automated Liquid Biopsies
Extracellular vesicles (EVs) are tiny particles released by cells into the bloodstream that carry molecular information about a cell’s condition, including whether it is cancerous. However, EVs are highly... Read more
Blood Test Identifies Inflammatory Breast Cancer Patients at Increased Risk of Brain Metastasis
Brain metastasis is a frequent and devastating complication in patients with inflammatory breast cancer, an aggressive subtype with limited treatment options. Despite its high incidence, the biological... Read moreHematology
view channel
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. Approximately 3,260 people in the United States are diagnosed... Read more
Fast and Easy Test Could Revolutionize Blood Transfusions
Blood transfusions are a cornerstone of modern medicine, yet red blood cells can deteriorate quietly while sitting in cold storage for weeks. Although blood units have a fixed expiration date, cells from... Read more
Automated Hemostasis System Helps Labs of All Sizes Optimize Workflow
High-volume hemostasis sections must sustain rapid turnaround while managing reruns and reflex testing. Manual tube handling and preanalytical checks can strain staff time and increase opportunities for error.... Read more
High-Sensitivity Blood Test Improves Assessment of Clotting Risk in Heart Disease Patients
Blood clotting is essential for preventing bleeding, but even small imbalances can lead to serious conditions such as thrombosis or dangerous hemorrhage. In cardiovascular disease, clinicians often struggle... Read moreImmunology
view channelBlood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug
Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more
Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment
Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more
Ultrasensitive Liquid Biopsy Demonstrates Efficacy in Predicting Immunotherapy Response
Immunotherapy has transformed cancer treatment, but only a small proportion of patients experience lasting benefit, with response rates often remaining between 10% and 20%. Clinicians currently lack reliable... Read moreMicrobiology
view channel
Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease
Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read moreAI-Powered Platform Enables Rapid Detection of Drug-Resistant C. Auris Pathogens
Infections caused by the pathogenic yeast Candida auris pose a significant threat to hospitalized patients, particularly those with weakened immune systems or those who have invasive medical devices.... Read morePathology
view channel
Engineered Yeast Cells Enable Rapid Testing of Cancer Immunotherapy
Developing new cancer immunotherapies is a slow, costly, and high-risk process, particularly for CAR T cell treatments that must precisely recognize cancer-specific antigens. Small differences in tumor... Read more
First-Of-Its-Kind Test Identifies Autism Risk at Birth
Autism spectrum disorder is treatable, and extensive research shows that early intervention can significantly improve cognitive, social, and behavioral outcomes. Yet in the United States, the average age... Read moreTechnology
view channel
Robotic Technology Unveiled for Automated Diagnostic Blood Draws
Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more
ADLM Launches First-of-Its-Kind Data Science Program for Laboratory Medicine Professionals
Clinical laboratories generate billions of test results each year, creating a treasure trove of data with the potential to support more personalized testing, improve operational efficiency, and enhance patient care.... Read moreAptamer Biosensor Technology to Transform Virus Detection
Rapid and reliable virus detection is essential for controlling outbreaks, from seasonal influenza to global pandemics such as COVID-19. Conventional diagnostic methods, including cell culture, antigen... Read more
AI Models Could Predict Pre-Eclampsia and Anemia Earlier Using Routine Blood Tests
Pre-eclampsia and anemia are major contributors to maternal and child mortality worldwide, together accounting for more than half a million deaths each year and leaving millions with long-term health complications.... Read moreIndustry
view channelNew Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing
Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
AI-Powered Cervical Cancer Test Set for Major Rollout in Latin America
Noul Co., a Korean company specializing in AI-based blood and cancer diagnostics, announced it will supply its intelligence (AI)-based miLab CER cervical cancer diagnostic solution to Mexico under a multi‑year... Read more
Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform
Diasorin (Saluggia, Italy) has entered into an exclusive distribution agreement with Fisher Scientific, part of Thermo Fisher Scientific (Waltham, MA, USA), for the LIAISON NES molecular point-of-care... Read more








